Literature DB >> 34341536

Directly reprogrammed natural killer cells for cancer immunotherapy.

Han-Seop Kim1, Jae Yun Kim1,2, Binna Seol1, Cho Lok Song1,2, Ji Eun Jeong1, Yee Sook Cho3,4.   

Abstract

Efficacious and accessible sources of natural killer (NK) cells would widen their use as immunotherapeutics, particularly for solid cancers. Here, we show that human somatic cells can be directly reprogrammed into NK cells with a CD56brightCD16bright phenotype using pluripotency transcription factors and an optimized reprogramming medium. The directly reprogrammed NK cells have strong innate-adaptive immunomodulatory activity and are highly potent against a wide range of cancer cells, including difficult-to-treat solid cancers and cancer stem cells. Both directly reprogrammed NK cells bearing a cancer-specific chimeric antigen receptor and reprogrammed NK cells in combination with antibodies competent for antibody-dependent cell-mediated cytotoxicity led to selective anticancer effects with augmented potency. The direct reprogramming of human somatic cells into NK cells is amenable to the production of autologous and allogeneic NK cells, and will facilitate the design and testing of cancer immunotherapies and combination therapies.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34341536     DOI: 10.1038/s41551-021-00768-z

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN: 2157-846X            Impact factor:   25.671


  50 in total

Review 1.  The biology of human natural killer-cell subsets.

Authors:  M A Cooper; T A Fehniger; M A Caligiuri
Journal:  Trends Immunol       Date:  2001-11       Impact factor: 16.687

Review 2.  The Broad Spectrum of Human Natural Killer Cell Diversity.

Authors:  Aharon G Freud; Bethany L Mundy-Bosse; Jianhua Yu; Michael A Caligiuri
Journal:  Immunity       Date:  2017-11-21       Impact factor: 31.745

3.  Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.

Authors:  Rossana Tallerico; Matilde Todaro; Simone Di Franco; Cristina Maccalli; Cinzia Garofalo; Rosa Sottile; Camillo Palmieri; Luca Tirinato; Pradeepa N Pangigadde; Rosanna La Rocca; Ofer Mandelboim; Giorgio Stassi; Enzo Di Fabrizio; Giorgio Parmiani; Alessandro Moretta; Francesco Dieli; Klas Kärre; Ennio Carbone
Journal:  J Immunol       Date:  2013-01-23       Impact factor: 5.422

Review 4.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

Review 5.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

Review 6.  The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells.

Authors:  Michael R Verneris; Jeffrey S Miller
Journal:  Br J Haematol       Date:  2009-10       Impact factor: 6.998

7.  Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma.

Authors:  Meriem Messaoudene; Giulia Fregni; Emmanuelle Fourmentraux-Neves; Johan Chanal; Eve Maubec; Sarra Mazouz-Dorval; Benoit Couturaud; Angelique Girod; Xavier Sastre-Garau; Sebastien Albert; Charles Guédon; Lydia Deschamps; Delphine Mitilian; Isabelle Cremer; Nicolas Jacquelot; Sylvie Rusakiewicz; Laurence Zitvogel; Marie-Francoise Avril; Anne Caignard
Journal:  Cancer Res       Date:  2013-11-13       Impact factor: 12.701

Review 8.  NK cells for cancer immunotherapy.

Authors:  Noriko Shimasaki; Amit Jain; Dario Campana
Journal:  Nat Rev Drug Discov       Date:  2020-01-06       Impact factor: 84.694

Review 9.  Natural killer cells and other innate lymphoid cells in cancer.

Authors:  Laura Chiossone; Pierre-Yves Dumas; Margaux Vienne; Eric Vivier
Journal:  Nat Rev Immunol       Date:  2018-11       Impact factor: 53.106

10.  Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56Dim NK cells.

Authors:  Evan Shereck; Nancy S Day; Aradhana Awasthi; Janet Ayello; Yaya Chu; Catherine McGuinn; Carmella van de Ven; Megan S Lim; Mitchell S Cairo
Journal:  Innate Immun       Date:  2019-05-08       Impact factor: 2.680

View more
  3 in total

Review 1.  Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.

Authors:  Roberta Mazza; John Maher
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-12-12       Impact factor: 4.291

Review 2.  Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.

Authors:  Katharina Eva Ruppel; Stephan Fricke; Ulrike Köhl; Dominik Schmiedel
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

Review 3.  Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.

Authors:  Yang Zhou; Miao Li; Kuangyi Zhou; James Brown; Tasha Tsao; Xinjian Cen; Tiffany Husman; Aarushi Bajpai; Zachary Spencer Dunn; Lili Yang
Journal:  Cancers (Basel)       Date:  2022-05-01       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.